Viridian is headquartered in Waltham, Massachusetts. For more information, please
visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.
Forward Looking Statements
This press release contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to,
“anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,”
“on track,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that
concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements
include, without limitation, statements regarding: differentiation and clinical benefit of VRDN-008, including its potential to have a
best-in-class profile, to be dosed every eight weeks, and to provide patients with an option for extended disease control and convenience; our clinical development and
regulatory plans, strategies and timelines for VRDN-008, including the design, timing and initiation of a potential pivotal clinical trial of VRDN-008 in myasthenia
gravis in mid-2027 pending regulatory feedback; our plans to conduct at least one registrational clinical trial of VRDN-008 in 2027; our expectation that we will be able
to rapidly advance VRDN-008 into registrational development; our plans to advance development of VRDN-008 with Q8W dosing; the potential for VRDN-008 and other product candidates to be best-in-class; our plans to expand VRDN-008
development into multiple autoimmune diseases; our plans to administer VRDN-008 using the Enable enFuse device; and our expectations regarding the potential commercialization, market size, and market
opportunities of VRDN-008, if approved.
New risks and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks
and uncertainties including but not limited to: that the company has historically incurred losses and may not be able to secure additional capital when needed; that the company may be unable to maintain commercial manufacturing, sales and marketing
capabilities or enter into agreements with third parties to commercially manufacture, market and sell its products or product candidates including VRDN-008; that the company may be unable to maintain or enter
into agreements with third parties, including Enable Injections, to support VRDN-008 development; that the potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of
VRDN-008 may be less than the Company anticipates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary
data may not be representative of final data; that feedback from regulatory authorities may require changes to, or delay, our planned development of VRDN-008, including the planned registrational clinical
trial in MG; uncertainty with respect to the timing, progress and plans for our ongoing or future research, preclinical, and clinical development programs; changes to trial protocols for ongoing or new clinical trials; changes regarding the timing
for regulatory filings; changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in our clinical programs, including as a result of
regulatory interactions; risks related to the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; manufacturing risks; competition from other therapies or products; any potential changes that impact
our estimates of market size and market opportunity; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; our financial position; future operating results and financial
performance not meeting our expectations; our ability to maintain and enforce our intellectual property position; adverse developments with respect to the timing of preclinical and clinical trial activities and reporting results from such
activities; that our product candidates may not be commercially successful, if approved; and other risks described from time to time in the “Risk Factors”
